93 related articles for article (PubMed ID: 30562867)
41. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
[TBL] [Abstract][Full Text] [Related]
42. Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang CL; Balint K; Coukos G; Kandalaft LE
Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
[TBL] [Abstract][Full Text] [Related]
43. Deregulated expression of CD40 ligand in HTLV-I infection: distinct mechanisms of downregulation in HTLV-I-transformed cell lines and ATL patients.
Harhaj NS; Janic B; Ramos JC; Harrington WJ; Harhaj EW
Virology; 2007 May; 362(1):99-108. PubMed ID: 17258259
[TBL] [Abstract][Full Text] [Related]
44. Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
Nasr R; Marçais A; Hermine O; Bazarbachi A
Methods Mol Biol; 2017; 1582():197-216. PubMed ID: 28357672
[TBL] [Abstract][Full Text] [Related]
45. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
[TBL] [Abstract][Full Text] [Related]
46. [Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice].
Zhao J; Lu J; Liu YQ; Yang HY; Huang YT; Zhao JM; Li S; Zhai JM; Zhao MY; Zhang X; Dong ZM
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):52-7. PubMed ID: 21429436
[TBL] [Abstract][Full Text] [Related]
47. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.
Smith SG; Patel PM; Porte J; Selby PJ; Jackson AM
Clin Cancer Res; 2001 Dec; 7(12):4253-61. PubMed ID: 11751527
[TBL] [Abstract][Full Text] [Related]
48. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
49. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
50. Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs.
Miki K; Nagaoka K; Harada M; Hayashi T; Jinguji H; Kato Y; Maekawa R
Int Immunopharmacol; 2014 Dec; 23(2):499-504. PubMed ID: 25284343
[TBL] [Abstract][Full Text] [Related]
51. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
52. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
53. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells.
Satou Y; Yasunaga J; Yoshida M; Matsuoka M
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):720-5. PubMed ID: 16407133
[TBL] [Abstract][Full Text] [Related]
54. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
[TBL] [Abstract][Full Text] [Related]
55. Activation of AID by human T-cell leukemia virus Tax oncoprotein and the possible role of its constitutive expression in ATL genesis.
Ishikawa C; Nakachi S; Senba M; Sugai M; Mori N
Carcinogenesis; 2011 Jan; 32(1):110-9. PubMed ID: 20974684
[TBL] [Abstract][Full Text] [Related]
56. HTLV-I viral escape and host genetic changes in the development of adult T cell leukemia.
Furukawa Y; Tara M; Izumo S; Arimura K; Osame M
Int J Cancer; 2006 Jan; 118(2):381-7. PubMed ID: 16052518
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
58. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms.
Yasunaga J; Matsuoka M
Cancer Control; 2007 Apr; 14(2):133-40. PubMed ID: 17387298
[TBL] [Abstract][Full Text] [Related]
59. Human T-cell leukemia virus type 1 Tax and cellular transformation.
Peloponese JM; Kinjo T; Jeang KT
Int J Hematol; 2007 Aug; 86(2):101-6. PubMed ID: 17875521
[TBL] [Abstract][Full Text] [Related]
60. [Killing effect of dendritic cell vaccine transfected by recombinant adeno-associated virus with hAFP gene fragment on hepatocellular carcinoma cells in vitro].
Sun JH; Ma YL; Peng ME; Bie AG; Li L; Liu L
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):334-8. PubMed ID: 20723429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
